nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—CYSLTR2—cardiovascular system—type 2 diabetes mellitus	0.0153	0.141	CbGeAlD
Nedocromil—FPR1—kidney—type 2 diabetes mellitus	0.0135	0.124	CbGeAlD
Nedocromil—HSP90AA1—endothelium—type 2 diabetes mellitus	0.0122	0.112	CbGeAlD
Nedocromil—PTGDR—adipose tissue—type 2 diabetes mellitus	0.0115	0.106	CbGeAlD
Nedocromil—HSP90AA1—islet of Langerhans—type 2 diabetes mellitus	0.00693	0.0637	CbGeAlD
Nedocromil—HSP90AA1—retina—type 2 diabetes mellitus	0.00593	0.0545	CbGeAlD
Nedocromil—CYSLTR1—pancreas—type 2 diabetes mellitus	0.00562	0.0516	CbGeAlD
Nedocromil—HSP90AA1—nephron tubule—type 2 diabetes mellitus	0.00558	0.0513	CbGeAlD
Nedocromil—CYSLTR1—adipose tissue—type 2 diabetes mellitus	0.00509	0.0468	CbGeAlD
Nedocromil—HSP90AA1—cardiovascular system—type 2 diabetes mellitus	0.00501	0.0461	CbGeAlD
Nedocromil—HSP90AA1—kidney—type 2 diabetes mellitus	0.0049	0.0451	CbGeAlD
Nedocromil—HSP90AA1—pancreas—type 2 diabetes mellitus	0.00487	0.0448	CbGeAlD
Nedocromil—HSP90AA1—cortex of kidney—type 2 diabetes mellitus	0.00478	0.0439	CbGeAlD
Nedocromil—HSP90AA1—adipose tissue—type 2 diabetes mellitus	0.00442	0.0406	CbGeAlD
Nedocromil—HSP90AA1—liver—type 2 diabetes mellitus	0.0031	0.0285	CbGeAlD
Nedocromil—Conjunctivitis—Losartan—type 2 diabetes mellitus	0.000794	0.00186	CcSEcCtD
Nedocromil—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.000793	0.00186	CcSEcCtD
Nedocromil—Influenza—Ramipril—type 2 diabetes mellitus	0.000785	0.00184	CcSEcCtD
Nedocromil—Rhinitis—Irbesartan—type 2 diabetes mellitus	0.000781	0.00183	CcSEcCtD
Nedocromil—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000779	0.00183	CcSEcCtD
Nedocromil—Eosinophilia—Ramipril—type 2 diabetes mellitus	0.000777	0.00183	CcSEcCtD
Nedocromil—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	0.000774	0.00182	CcSEcCtD
Nedocromil—Pharyngitis—Irbesartan—type 2 diabetes mellitus	0.000773	0.00182	CcSEcCtD
Nedocromil—Rash—Repaglinide—type 2 diabetes mellitus	0.000773	0.00182	CcSEcCtD
Nedocromil—Dysgeusia—Valsartan—type 2 diabetes mellitus	0.000773	0.00181	CcSEcCtD
Nedocromil—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000772	0.00181	CcSEcCtD
Nedocromil—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.000772	0.00181	CcSEcCtD
Nedocromil—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	0.000771	0.00181	CcSEcCtD
Nedocromil—Leukopenia—Gliclazide—type 2 diabetes mellitus	0.000769	0.00181	CcSEcCtD
Nedocromil—Headache—Repaglinide—type 2 diabetes mellitus	0.000768	0.0018	CcSEcCtD
Nedocromil—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000766	0.0018	CcSEcCtD
Nedocromil—Sinusitis—Losartan—type 2 diabetes mellitus	0.000766	0.0018	CcSEcCtD
Nedocromil—Dysgeusia—Orlistat—type 2 diabetes mellitus	0.000763	0.00179	CcSEcCtD
Nedocromil—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.000761	0.00179	CcSEcCtD
Nedocromil—Bronchitis—Ramipril—type 2 diabetes mellitus	0.000755	0.00177	CcSEcCtD
Nedocromil—Urticaria—Glimepiride—type 2 diabetes mellitus	0.000752	0.00177	CcSEcCtD
Nedocromil—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	0.000751	0.00177	CcSEcCtD
Nedocromil—Visual impairment—Irbesartan—type 2 diabetes mellitus	0.000751	0.00176	CcSEcCtD
Nedocromil—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.000749	0.00176	CcSEcCtD
Nedocromil—Cough—Gliclazide—type 2 diabetes mellitus	0.000749	0.00176	CcSEcCtD
Nedocromil—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.000748	0.00176	CcSEcCtD
Nedocromil—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000747	0.00176	CcSEcCtD
Nedocromil—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.000746	0.00175	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000737	0.00173	CcSEcCtD
Nedocromil—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000736	0.00173	CcSEcCtD
Nedocromil—Rhinitis—Losartan—type 2 diabetes mellitus	0.000735	0.00173	CcSEcCtD
Nedocromil—Chest pain—Gliclazide—type 2 diabetes mellitus	0.000731	0.00172	CcSEcCtD
Nedocromil—Rash—Rosiglitazone—type 2 diabetes mellitus	0.00073	0.00172	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Ramipril—type 2 diabetes mellitus	0.00073	0.00171	CcSEcCtD
Nedocromil—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.00073	0.00171	CcSEcCtD
Nedocromil—Nausea—Repaglinide—type 2 diabetes mellitus	0.000728	0.00171	CcSEcCtD
Nedocromil—Asthenia—Glipizide—type 2 diabetes mellitus	0.000728	0.00171	CcSEcCtD
Nedocromil—Pharyngitis—Losartan—type 2 diabetes mellitus	0.000727	0.00171	CcSEcCtD
Nedocromil—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000726	0.0017	CcSEcCtD
Nedocromil—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000716	0.00168	CcSEcCtD
Nedocromil—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.000715	0.00168	CcSEcCtD
Nedocromil—Dysgeusia—Metformin—type 2 diabetes mellitus	0.000703	0.00165	CcSEcCtD
Nedocromil—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.000698	0.00164	CcSEcCtD
Nedocromil—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000697	0.00164	CcSEcCtD
Nedocromil—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000697	0.00164	CcSEcCtD
Nedocromil—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000696	0.00163	CcSEcCtD
Nedocromil—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000695	0.00163	CcSEcCtD
Nedocromil—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000694	0.00163	CcSEcCtD
Nedocromil—Cough—Valsartan—type 2 diabetes mellitus	0.000688	0.00162	CcSEcCtD
Nedocromil—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000688	0.00162	CcSEcCtD
Nedocromil—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000687	0.00161	CcSEcCtD
Nedocromil—Conjunctivitis—Ramipril—type 2 diabetes mellitus	0.00068	0.0016	CcSEcCtD
Nedocromil—Cough—Orlistat—type 2 diabetes mellitus	0.00068	0.0016	CcSEcCtD
Nedocromil—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000679	0.00159	CcSEcCtD
Nedocromil—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000678	0.00159	CcSEcCtD
Nedocromil—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000677	0.00159	CcSEcCtD
Nedocromil—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000675	0.00159	CcSEcCtD
Nedocromil—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000675	0.00159	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000674	0.00158	CcSEcCtD
Nedocromil—Tremor—Metformin—type 2 diabetes mellitus	0.000673	0.00158	CcSEcCtD
Nedocromil—Chest pain—Valsartan—type 2 diabetes mellitus	0.000672	0.00158	CcSEcCtD
Nedocromil—Dizziness—Glipizide—type 2 diabetes mellitus	0.000671	0.00158	CcSEcCtD
Nedocromil—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000665	0.00156	CcSEcCtD
Nedocromil—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000664	0.00156	CcSEcCtD
Nedocromil—Chest pain—Orlistat—type 2 diabetes mellitus	0.000664	0.00156	CcSEcCtD
Nedocromil—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000657	0.00154	CcSEcCtD
Nedocromil—Sinusitis—Ramipril—type 2 diabetes mellitus	0.000657	0.00154	CcSEcCtD
Nedocromil—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000649	0.00152	CcSEcCtD
Nedocromil—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000647	0.00152	CcSEcCtD
Nedocromil—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000645	0.00152	CcSEcCtD
Nedocromil—Vomiting—Glipizide—type 2 diabetes mellitus	0.000645	0.00151	CcSEcCtD
Nedocromil—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.000644	0.00151	CcSEcCtD
Nedocromil—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000642	0.00151	CcSEcCtD
Nedocromil—Rash—Glipizide—type 2 diabetes mellitus	0.000639	0.0015	CcSEcCtD
Nedocromil—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000639	0.0015	CcSEcCtD
Nedocromil—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000638	0.0015	CcSEcCtD
Nedocromil—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000636	0.00149	CcSEcCtD
Nedocromil—Headache—Glipizide—type 2 diabetes mellitus	0.000635	0.00149	CcSEcCtD
Nedocromil—Tremor—Irbesartan—type 2 diabetes mellitus	0.000635	0.00149	CcSEcCtD
Nedocromil—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000626	0.00147	CcSEcCtD
Nedocromil—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000625	0.00147	CcSEcCtD
Nedocromil—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000625	0.00147	CcSEcCtD
Nedocromil—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000624	0.00147	CcSEcCtD
Nedocromil—Urticaria—Glyburide—type 2 diabetes mellitus	0.00062	0.00146	CcSEcCtD
Nedocromil—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000617	0.00145	CcSEcCtD
Nedocromil—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000617	0.00145	CcSEcCtD
Nedocromil—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000613	0.00144	CcSEcCtD
Nedocromil—Chest pain—Metformin—type 2 diabetes mellitus	0.000612	0.00144	CcSEcCtD
Nedocromil—Headache—Pioglitazone—type 2 diabetes mellitus	0.000609	0.00143	CcSEcCtD
Nedocromil—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.000607	0.00143	CcSEcCtD
Nedocromil—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000606	0.00142	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000605	0.00142	CcSEcCtD
Nedocromil—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000604	0.00142	CcSEcCtD
Nedocromil—Nausea—Glipizide—type 2 diabetes mellitus	0.000602	0.00141	CcSEcCtD
Nedocromil—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000602	0.00141	CcSEcCtD
Nedocromil—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.0006	0.00141	CcSEcCtD
Nedocromil—Pain—Gliclazide—type 2 diabetes mellitus	0.000599	0.00141	CcSEcCtD
Nedocromil—Tremor—Losartan—type 2 diabetes mellitus	0.000598	0.0014	CcSEcCtD
Nedocromil—Rash—Glimepiride—type 2 diabetes mellitus	0.000597	0.0014	CcSEcCtD
Nedocromil—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000596	0.0014	CcSEcCtD
Nedocromil—Rash—Sitagliptin—type 2 diabetes mellitus	0.000595	0.0014	CcSEcCtD
Nedocromil—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000594	0.0014	CcSEcCtD
Nedocromil—Headache—Glimepiride—type 2 diabetes mellitus	0.000593	0.00139	CcSEcCtD
Nedocromil—Cough—Irbesartan—type 2 diabetes mellitus	0.000592	0.00139	CcSEcCtD
Nedocromil—Headache—Sitagliptin—type 2 diabetes mellitus	0.000591	0.00139	CcSEcCtD
Nedocromil—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000584	0.00137	CcSEcCtD
Nedocromil—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000577	0.00136	CcSEcCtD
Nedocromil—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000575	0.00135	CcSEcCtD
Nedocromil—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000574	0.00135	CcSEcCtD
Nedocromil—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000573	0.00135	CcSEcCtD
Nedocromil—Leukopenia—Losartan—type 2 diabetes mellitus	0.000571	0.00134	CcSEcCtD
Nedocromil—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000567	0.00133	CcSEcCtD
Nedocromil—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000565	0.00133	CcSEcCtD
Nedocromil—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000564	0.00133	CcSEcCtD
Nedocromil—Nausea—Glimepiride—type 2 diabetes mellitus	0.000562	0.00132	CcSEcCtD
Nedocromil—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00056	0.00132	CcSEcCtD
Nedocromil—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.00056	0.00132	CcSEcCtD
Nedocromil—Asthenia—Glyburide—type 2 diabetes mellitus	0.00056	0.00132	CcSEcCtD
Nedocromil—Cough—Losartan—type 2 diabetes mellitus	0.000557	0.00131	CcSEcCtD
Nedocromil—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000557	0.00131	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000556	0.00131	CcSEcCtD
Nedocromil—Fatigue—Valsartan—type 2 diabetes mellitus	0.000555	0.0013	CcSEcCtD
Nedocromil—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000554	0.0013	CcSEcCtD
Nedocromil—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000554	0.0013	CcSEcCtD
Nedocromil—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000553	0.0013	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000549	0.00129	CcSEcCtD
Nedocromil—Fatigue—Orlistat—type 2 diabetes mellitus	0.000548	0.00129	CcSEcCtD
Nedocromil—Pain—Orlistat—type 2 diabetes mellitus	0.000544	0.00128	CcSEcCtD
Nedocromil—Chest pain—Losartan—type 2 diabetes mellitus	0.000543	0.00128	CcSEcCtD
Nedocromil—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000543	0.00128	CcSEcCtD
Nedocromil—Rash—Bromocriptine—type 2 diabetes mellitus	0.000538	0.00126	CcSEcCtD
Nedocromil—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000538	0.00126	CcSEcCtD
Nedocromil—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000536	0.00126	CcSEcCtD
Nedocromil—Headache—Bromocriptine—type 2 diabetes mellitus	0.000535	0.00126	CcSEcCtD
Nedocromil—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000534	0.00125	CcSEcCtD
Nedocromil—Dry mouth—Losartan—type 2 diabetes mellitus	0.000531	0.00125	CcSEcCtD
Nedocromil—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000526	0.00124	CcSEcCtD
Nedocromil—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000523	0.00123	CcSEcCtD
Nedocromil—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000521	0.00122	CcSEcCtD
Nedocromil—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.00052	0.00122	CcSEcCtD
Nedocromil—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000516	0.00121	CcSEcCtD
Nedocromil—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000516	0.00121	CcSEcCtD
Nedocromil—Tremor—Ramipril—type 2 diabetes mellitus	0.000513	0.0012	CcSEcCtD
Nedocromil—Urticaria—Valsartan—type 2 diabetes mellitus	0.000511	0.0012	CcSEcCtD
Nedocromil—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000509	0.0012	CcSEcCtD
Nedocromil—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000507	0.00119	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000506	0.00119	CcSEcCtD
Nedocromil—Fatigue—Metformin—type 2 diabetes mellitus	0.000505	0.00119	CcSEcCtD
Nedocromil—Urticaria—Orlistat—type 2 diabetes mellitus	0.000505	0.00119	CcSEcCtD
Nedocromil—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000503	0.00118	CcSEcCtD
Nedocromil—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000503	0.00118	CcSEcCtD
Nedocromil—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000503	0.00118	CcSEcCtD
Nedocromil—Vomiting—Glyburide—type 2 diabetes mellitus	0.000496	0.00117	CcSEcCtD
Nedocromil—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000493	0.00116	CcSEcCtD
Nedocromil—Rash—Glyburide—type 2 diabetes mellitus	0.000492	0.00116	CcSEcCtD
Nedocromil—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000492	0.00115	CcSEcCtD
Nedocromil—Leukopenia—Ramipril—type 2 diabetes mellitus	0.00049	0.00115	CcSEcCtD
Nedocromil—Headache—Glyburide—type 2 diabetes mellitus	0.000489	0.00115	CcSEcCtD
Nedocromil—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000487	0.00114	CcSEcCtD
Nedocromil—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000479	0.00113	CcSEcCtD
Nedocromil—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000479	0.00113	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000478	0.00112	CcSEcCtD
Nedocromil—Cough—Ramipril—type 2 diabetes mellitus	0.000477	0.00112	CcSEcCtD
Nedocromil—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000477	0.00112	CcSEcCtD
Nedocromil—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000474	0.00111	CcSEcCtD
Nedocromil—Pain—Irbesartan—type 2 diabetes mellitus	0.000473	0.00111	CcSEcCtD
Nedocromil—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000469	0.0011	CcSEcCtD
Nedocromil—Urticaria—Metformin—type 2 diabetes mellitus	0.000466	0.00109	CcSEcCtD
Nedocromil—Chest pain—Ramipril—type 2 diabetes mellitus	0.000466	0.00109	CcSEcCtD
Nedocromil—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000464	0.00109	CcSEcCtD
Nedocromil—Nausea—Glyburide—type 2 diabetes mellitus	0.000464	0.00109	CcSEcCtD
Nedocromil—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000463	0.00109	CcSEcCtD
Nedocromil—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000463	0.00109	CcSEcCtD
Nedocromil—Asthenia—Valsartan—type 2 diabetes mellitus	0.000462	0.00109	CcSEcCtD
Nedocromil—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000458	0.00108	CcSEcCtD
Nedocromil—Asthenia—Orlistat—type 2 diabetes mellitus	0.000456	0.00107	CcSEcCtD
Nedocromil—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000456	0.00107	CcSEcCtD
Nedocromil—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000452	0.00106	CcSEcCtD
Nedocromil—Fatigue—Losartan—type 2 diabetes mellitus	0.000449	0.00105	CcSEcCtD
Nedocromil—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000446	0.00105	CcSEcCtD
Nedocromil—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000446	0.00105	CcSEcCtD
Nedocromil—Pain—Losartan—type 2 diabetes mellitus	0.000445	0.00105	CcSEcCtD
Nedocromil—Rash—Gliclazide—type 2 diabetes mellitus	0.000442	0.00104	CcSEcCtD
Nedocromil—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000441	0.00104	CcSEcCtD
Nedocromil—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000441	0.00103	CcSEcCtD
Nedocromil—Urticaria—Irbesartan—type 2 diabetes mellitus	0.00044	0.00103	CcSEcCtD
Nedocromil—Headache—Gliclazide—type 2 diabetes mellitus	0.000439	0.00103	CcSEcCtD
Nedocromil—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000437	0.00103	CcSEcCtD
Nedocromil—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000437	0.00103	CcSEcCtD
Nedocromil—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000435	0.00102	CcSEcCtD
Nedocromil—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000426	0.001	CcSEcCtD
Nedocromil—Dizziness—Valsartan—type 2 diabetes mellitus	0.000426	0.001	CcSEcCtD
Nedocromil—Dizziness—Orlistat—type 2 diabetes mellitus	0.000421	0.000988	CcSEcCtD
Nedocromil—Asthenia—Metformin—type 2 diabetes mellitus	0.000421	0.000988	CcSEcCtD
Nedocromil—Nausea—Gliclazide—type 2 diabetes mellitus	0.000416	0.000978	CcSEcCtD
Nedocromil—Urticaria—Losartan—type 2 diabetes mellitus	0.000414	0.000972	CcSEcCtD
Nedocromil—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000412	0.000967	CcSEcCtD
Nedocromil—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000412	0.000967	CcSEcCtD
Nedocromil—Vomiting—Valsartan—type 2 diabetes mellitus	0.000409	0.000962	CcSEcCtD
Nedocromil—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000408	0.000958	CcSEcCtD
Nedocromil—Rash—Valsartan—type 2 diabetes mellitus	0.000406	0.000954	CcSEcCtD
Nedocromil—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000406	0.000953	CcSEcCtD
Nedocromil—Vomiting—Orlistat—type 2 diabetes mellitus	0.000404	0.00095	CcSEcCtD
Nedocromil—Headache—Valsartan—type 2 diabetes mellitus	0.000403	0.000947	CcSEcCtD
Nedocromil—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000401	0.000942	CcSEcCtD
Nedocromil—Rash—Orlistat—type 2 diabetes mellitus	0.000401	0.000942	CcSEcCtD
Nedocromil—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000401	0.000941	CcSEcCtD
Nedocromil—Headache—Orlistat—type 2 diabetes mellitus	0.000399	0.000936	CcSEcCtD
Nedocromil—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000398	0.000935	CcSEcCtD
Nedocromil—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000397	0.000933	CcSEcCtD
Nedocromil—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000393	0.000923	CcSEcCtD
Nedocromil—Dizziness—Metformin—type 2 diabetes mellitus	0.000388	0.000911	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000385	0.000905	CcSEcCtD
Nedocromil—Fatigue—Ramipril—type 2 diabetes mellitus	0.000385	0.000904	CcSEcCtD
Nedocromil—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000384	0.000901	CcSEcCtD
Nedocromil—Nausea—Valsartan—type 2 diabetes mellitus	0.000382	0.000898	CcSEcCtD
Nedocromil—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000379	0.000889	CcSEcCtD
Nedocromil—Nausea—Orlistat—type 2 diabetes mellitus	0.000378	0.000888	CcSEcCtD
Nedocromil—Asthenia—Losartan—type 2 diabetes mellitus	0.000374	0.000878	CcSEcCtD
Nedocromil—Vomiting—Metformin—type 2 diabetes mellitus	0.000373	0.000876	CcSEcCtD
Nedocromil—Rash—Metformin—type 2 diabetes mellitus	0.00037	0.000868	CcSEcCtD
Nedocromil—Dermatitis—Metformin—type 2 diabetes mellitus	0.000369	0.000868	CcSEcCtD
Nedocromil—Headache—Metformin—type 2 diabetes mellitus	0.000367	0.000863	CcSEcCtD
Nedocromil—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000366	0.000859	CcSEcCtD
Nedocromil—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000365	0.000858	CcSEcCtD
Nedocromil—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000356	0.000837	CcSEcCtD
Nedocromil—Urticaria—Ramipril—type 2 diabetes mellitus	0.000355	0.000833	CcSEcCtD
Nedocromil—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.000353	0.000829	CcSEcCtD
Nedocromil—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000353	0.000829	CcSEcCtD
Nedocromil—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000352	0.000826	CcSEcCtD
Nedocromil—Rash—Irbesartan—type 2 diabetes mellitus	0.000349	0.00082	CcSEcCtD
Nedocromil—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000349	0.000819	CcSEcCtD
Nedocromil—Nausea—Metformin—type 2 diabetes mellitus	0.000348	0.000818	CcSEcCtD
Nedocromil—Headache—Irbesartan—type 2 diabetes mellitus	0.000347	0.000814	CcSEcCtD
Nedocromil—Dizziness—Losartan—type 2 diabetes mellitus	0.000344	0.000809	CcSEcCtD
Nedocromil—Vomiting—Losartan—type 2 diabetes mellitus	0.000331	0.000778	CcSEcCtD
Nedocromil—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000329	0.000773	CcSEcCtD
Nedocromil—Nausea—Irbesartan—type 2 diabetes mellitus	0.000329	0.000772	CcSEcCtD
Nedocromil—Rash—Losartan—type 2 diabetes mellitus	0.000328	0.000771	CcSEcCtD
Nedocromil—Dermatitis—Losartan—type 2 diabetes mellitus	0.000328	0.000771	CcSEcCtD
Nedocromil—Headache—Losartan—type 2 diabetes mellitus	0.000326	0.000766	CcSEcCtD
Nedocromil—Asthenia—Ramipril—type 2 diabetes mellitus	0.00032	0.000753	CcSEcCtD
Nedocromil—Nausea—Losartan—type 2 diabetes mellitus	0.000309	0.000727	CcSEcCtD
Nedocromil—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000305	0.000718	CcSEcCtD
Nedocromil—Dizziness—Ramipril—type 2 diabetes mellitus	0.000295	0.000694	CcSEcCtD
Nedocromil—Vomiting—Ramipril—type 2 diabetes mellitus	0.000284	0.000667	CcSEcCtD
Nedocromil—Rash—Ramipril—type 2 diabetes mellitus	0.000282	0.000661	CcSEcCtD
Nedocromil—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000281	0.000661	CcSEcCtD
Nedocromil—Headache—Ramipril—type 2 diabetes mellitus	0.00028	0.000657	CcSEcCtD
Nedocromil—Nausea—Ramipril—type 2 diabetes mellitus	0.000265	0.000623	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—IAPP—type 2 diabetes mellitus	5.09e-05	0.000109	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—INSR—type 2 diabetes mellitus	5.06e-05	0.000109	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.03e-05	0.000108	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.03e-05	0.000108	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CYP2E1—type 2 diabetes mellitus	5.02e-05	0.000108	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—BCL2—type 2 diabetes mellitus	5.02e-05	0.000108	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	4.97e-05	0.000107	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CYP1A2—type 2 diabetes mellitus	4.97e-05	0.000107	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—SLC2A1—type 2 diabetes mellitus	4.97e-05	0.000107	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.96e-05	0.000107	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TGFBR2—type 2 diabetes mellitus	4.95e-05	0.000106	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	4.94e-05	0.000106	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—RELA—type 2 diabetes mellitus	4.9e-05	0.000105	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—RELA—type 2 diabetes mellitus	4.9e-05	0.000105	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—IL6—type 2 diabetes mellitus	4.85e-05	0.000104	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CYP3A4—type 2 diabetes mellitus	4.84e-05	0.000104	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	4.83e-05	0.000104	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN2B—type 2 diabetes mellitus	4.79e-05	0.000103	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—GNB3—type 2 diabetes mellitus	4.78e-05	0.000103	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GCG—type 2 diabetes mellitus	4.76e-05	0.000102	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—SLC2A4—type 2 diabetes mellitus	4.76e-05	0.000102	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AGER—type 2 diabetes mellitus	4.75e-05	0.000102	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—MMP9—type 2 diabetes mellitus	4.73e-05	0.000102	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ADCY5—type 2 diabetes mellitus	4.73e-05	0.000102	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—RELA—type 2 diabetes mellitus	4.73e-05	0.000102	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	4.73e-05	0.000102	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AVP—type 2 diabetes mellitus	4.72e-05	0.000101	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MMP3—type 2 diabetes mellitus	4.72e-05	0.000101	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IGF2—type 2 diabetes mellitus	4.7e-05	0.000101	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.7e-05	0.000101	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—NFKB1—type 2 diabetes mellitus	4.68e-05	0.000101	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	4.68e-05	0.0001	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APOB—type 2 diabetes mellitus	4.67e-05	0.0001	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	4.63e-05	9.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	4.59e-05	9.87e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	4.59e-05	9.87e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CD36—type 2 diabetes mellitus	4.59e-05	9.86e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APOB—type 2 diabetes mellitus	4.56e-05	9.79e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.54e-05	9.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PPP2CA—type 2 diabetes mellitus	4.53e-05	9.74e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—INS—type 2 diabetes mellitus	4.5e-05	9.66e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.49e-05	9.64e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	4.47e-05	9.6e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—LPL—type 2 diabetes mellitus	4.46e-05	9.59e-05	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.46e-05	9.58e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CYBA—type 2 diabetes mellitus	4.45e-05	9.56e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.42e-05	9.51e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.42e-05	9.49e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.39e-05	9.43e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	4.37e-05	9.39e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ADCY5—type 2 diabetes mellitus	4.37e-05	9.38e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—SRC—type 2 diabetes mellitus	4.36e-05	9.38e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—GHRL—type 2 diabetes mellitus	4.35e-05	9.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PLAT—type 2 diabetes mellitus	4.35e-05	9.35e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—LPL—type 2 diabetes mellitus	4.35e-05	9.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—C3—type 2 diabetes mellitus	4.35e-05	9.35e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.35e-05	9.34e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.35e-05	9.34e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.33e-05	9.3e-05	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.31e-05	9.25e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CALCA—type 2 diabetes mellitus	4.3e-05	9.24e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.27e-05	9.17e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.26e-05	9.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—VEGFA—type 2 diabetes mellitus	4.25e-05	9.13e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.24e-05	9.11e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PPP2CA—type 2 diabetes mellitus	4.19e-05	8.99e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.18e-05	8.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—BCL2L1—type 2 diabetes mellitus	4.17e-05	8.95e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CRP—type 2 diabetes mellitus	4.14e-05	8.89e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IRS2—type 2 diabetes mellitus	4.14e-05	8.89e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—NFKB1—type 2 diabetes mellitus	4.14e-05	8.89e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.13e-05	8.87e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.13e-05	8.87e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—IL6—type 2 diabetes mellitus	4.12e-05	8.85e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CCR5—type 2 diabetes mellitus	4.11e-05	8.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.1e-05	8.82e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GNB3—type 2 diabetes mellitus	4.1e-05	8.82e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—HMOX1—type 2 diabetes mellitus	4.09e-05	8.78e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.08e-05	8.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CALM1—type 2 diabetes mellitus	4.07e-05	8.73e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	4.05e-05	8.7e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.05e-05	8.7e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.03e-05	8.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CAT—type 2 diabetes mellitus	4.03e-05	8.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MTHFR—type 2 diabetes mellitus	4.02e-05	8.63e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.01e-05	8.62e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.99e-05	8.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—GCG—type 2 diabetes mellitus	3.98e-05	8.55e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	3.98e-05	8.55e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.94e-05	8.47e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.94e-05	8.47e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—C3—type 2 diabetes mellitus	3.92e-05	8.42e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	3.92e-05	8.42e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—APOB—type 2 diabetes mellitus	3.91e-05	8.41e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.91e-05	8.4e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	3.9e-05	8.39e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—TGFB1—type 2 diabetes mellitus	3.9e-05	8.38e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—SRC—type 2 diabetes mellitus	3.85e-05	8.28e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—SRC—type 2 diabetes mellitus	3.85e-05	8.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HIF1A—type 2 diabetes mellitus	3.83e-05	8.23e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—EGFR—type 2 diabetes mellitus	3.83e-05	8.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IRS2—type 2 diabetes mellitus	3.82e-05	8.21e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PRKCB—type 2 diabetes mellitus	3.82e-05	8.21e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GSTM1—type 2 diabetes mellitus	3.81e-05	8.18e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ICAM1—type 2 diabetes mellitus	3.8e-05	8.17e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CALM1—type 2 diabetes mellitus	3.75e-05	8.06e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.75e-05	8.05e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APOE—type 2 diabetes mellitus	3.74e-05	8.03e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.74e-05	8.03e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—LPL—type 2 diabetes mellitus	3.74e-05	8.03e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.73e-05	8.01e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AGT—type 2 diabetes mellitus	3.72e-05	8e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—SRC—type 2 diabetes mellitus	3.72e-05	7.99e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—RELA—type 2 diabetes mellitus	3.71e-05	7.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APOA1—type 2 diabetes mellitus	3.7e-05	7.94e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.66e-05	7.87e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ADCY5—type 2 diabetes mellitus	3.66e-05	7.86e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—LEP—type 2 diabetes mellitus	3.65e-05	7.84e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APOE—type 2 diabetes mellitus	3.65e-05	7.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GPX1—type 2 diabetes mellitus	3.65e-05	7.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—TNF—type 2 diabetes mellitus	3.64e-05	7.83e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.62e-05	7.78e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IRS1—type 2 diabetes mellitus	3.61e-05	7.76e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.61e-05	7.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CD36—type 2 diabetes mellitus	3.55e-05	7.63e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PPP2CA—type 2 diabetes mellitus	3.51e-05	7.53e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOS2—type 2 diabetes mellitus	3.49e-05	7.49e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	3.46e-05	7.44e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.44e-05	7.39e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.44e-05	7.39e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—GNB3—type 2 diabetes mellitus	3.43e-05	7.37e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CASP8—type 2 diabetes mellitus	3.4e-05	7.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AVP—type 2 diabetes mellitus	3.39e-05	7.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP3—type 2 diabetes mellitus	3.39e-05	7.27e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.38e-05	7.26e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—EGFR—type 2 diabetes mellitus	3.38e-05	7.26e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.37e-05	7.25e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF2—type 2 diabetes mellitus	3.37e-05	7.24e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—MTHFR—type 2 diabetes mellitus	3.36e-05	7.23e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	3.36e-05	7.21e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.35e-05	7.19e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT2—type 2 diabetes mellitus	3.34e-05	7.19e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IRS1—type 2 diabetes mellitus	3.34e-05	7.17e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.33e-05	7.15e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.32e-05	7.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PPARA—type 2 diabetes mellitus	3.3e-05	7.09e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APOB—type 2 diabetes mellitus	3.27e-05	7.03e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.26e-05	7e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.26e-05	7e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.26e-05	6.99e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.22e-05	6.92e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AGT—type 2 diabetes mellitus	3.2e-05	6.87e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—INS—type 2 diabetes mellitus	3.2e-05	6.86e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.16e-05	6.8e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CALM1—type 2 diabetes mellitus	3.14e-05	6.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—APOE—type 2 diabetes mellitus	3.13e-05	6.73e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.13e-05	6.73e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—LPL—type 2 diabetes mellitus	3.12e-05	6.71e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—INS—type 2 diabetes mellitus	3.12e-05	6.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—APOA1—type 2 diabetes mellitus	3.1e-05	6.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT2—type 2 diabetes mellitus	3.09e-05	6.63e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.07e-05	6.59e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.07e-05	6.59e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.06e-05	6.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3R1—type 2 diabetes mellitus	3.03e-05	6.52e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.02e-05	6.48e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.01e-05	6.47e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3e-05	6.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—IL6—type 2 diabetes mellitus	2.94e-05	6.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SERPINE1—type 2 diabetes mellitus	2.93e-05	6.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.93e-05	6.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—BCL2—type 2 diabetes mellitus	2.92e-05	6.28e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SRC—type 2 diabetes mellitus	2.92e-05	6.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.88e-05	6.18e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.86e-05	6.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—RELA—type 2 diabetes mellitus	2.86e-05	6.14e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.84e-05	6.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—C3—type 2 diabetes mellitus	2.81e-05	6.04e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3R1—type 2 diabetes mellitus	2.8e-05	6.02e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOS3—type 2 diabetes mellitus	2.8e-05	6.02e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.73e-05	5.87e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.73e-05	5.87e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PPARG—type 2 diabetes mellitus	2.73e-05	5.86e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—AKT1—type 2 diabetes mellitus	2.71e-05	5.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.68e-05	5.76e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.68e-05	5.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—INS—type 2 diabetes mellitus	2.68e-05	5.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AGT—type 2 diabetes mellitus	2.67e-05	5.74e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.63e-05	5.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—LEP—type 2 diabetes mellitus	2.62e-05	5.63e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APOE—type 2 diabetes mellitus	2.62e-05	5.63e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.61e-05	5.6e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—IL6—type 2 diabetes mellitus	2.6e-05	5.58e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.59e-05	5.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.59e-05	5.56e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.57e-05	5.53e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTGS2—type 2 diabetes mellitus	2.56e-05	5.51e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.56e-05	5.49e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL6—type 2 diabetes mellitus	2.5e-05	5.38e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.47e-05	5.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ALB—type 2 diabetes mellitus	2.45e-05	5.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NFKB1—type 2 diabetes mellitus	2.41e-05	5.18e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—AKT1—type 2 diabetes mellitus	2.4e-05	5.15e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.39e-05	5.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3R1—type 2 diabetes mellitus	2.35e-05	5.04e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—NOS3—type 2 diabetes mellitus	2.35e-05	5.04e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.34e-05	5.03e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.34e-05	5.02e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.32e-05	4.99e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.31e-05	4.96e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.31e-05	4.95e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—SRC—type 2 diabetes mellitus	2.24e-05	4.82e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—INS—type 2 diabetes mellitus	2.24e-05	4.81e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.2e-05	4.73e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.19e-05	4.71e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.17e-05	4.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.16e-05	4.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.16e-05	4.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTGS2—type 2 diabetes mellitus	2.15e-05	4.61e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.13e-05	4.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SRC—type 2 diabetes mellitus	2.07e-05	4.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.06e-05	4.42e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.02e-05	4.34e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.97e-05	4.23e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGFR—type 2 diabetes mellitus	1.97e-05	4.23e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.97e-05	4.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.96e-05	4.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.96e-05	4.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TGFB1—type 2 diabetes mellitus	1.85e-05	3.98e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RELA—type 2 diabetes mellitus	1.85e-05	3.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGFR—type 2 diabetes mellitus	1.82e-05	3.9e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.81e-05	3.89e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.81e-05	3.88e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.77e-05	3.81e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.67e-05	3.58e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.57e-05	3.38e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.56e-05	3.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6—type 2 diabetes mellitus	1.51e-05	3.25e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.45e-05	3.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.41e-05	3.04e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6—type 2 diabetes mellitus	1.4e-05	3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT1—type 2 diabetes mellitus	1.4e-05	3e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.36e-05	2.93e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.3e-05	2.79e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT1—type 2 diabetes mellitus	1.29e-05	2.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.27e-05	2.73e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.26e-05	2.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKT1—type 2 diabetes mellitus	1.08e-05	2.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6—type 2 diabetes mellitus	9.78e-06	2.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.02e-06	1.94e-05	CbGpPWpGaD
